Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Lymphoblastic Leukemia
15%
Acute Myeloid Leukemia
51%
Adriamycin Bleomycin Vinblastine Dacarbazine
15%
Adverse Event
16%
Allogeneic Hematopoietic Stem Cell Transplantation
22%
Allogeneic Stem Cell Transplantation
34%
Anthracycline
12%
Autologous Stem Cell Transplantation
33%
B Cell
15%
B-Cell Chronic Lymphocytic Leukemia
20%
B-Cell Lymphoma
28%
Brentuximab Vedotin
13%
Cancer
14%
Cell Therapy
17%
Chemotherapy
51%
Chimeric Antigen Receptor
21%
Chimeric Antigen Receptor T-Cell
74%
Chimeric Antigen Receptor T-Cell Immunotherapy
46%
Computer Assisted Tomography
14%
Cyclophosphamide
24%
Cytokine Release Syndrome
18%
Diffuse Large B-Cell Lymphoma
27%
Diseases
66%
Drug Megadose
16%
Fludarabine
14%
Fluorine-18
13%
Hazard Ratio
24%
Hematopoietic Stem Cell Transplantation
13%
Hemoglobins
12%
High Dose Chemotherapy
17%
Hodgkin's Lymphoma
46%
Ibritumomab Tiuxetan
13%
Induction Chemotherapy
14%
Infusion
17%
Large-Cell Lymphoma
40%
Median Follow Up
18%
Multiple Myeloma
28%
Multivariate Analysis
13%
Myelodysplastic Syndrome
15%
Non-Hodgkin Lymphoma
52%
Overall Survival
73%
Polyethylene Terephthalate
15%
Positron Emission Tomography
15%
Positron Emission Tomography-Computed Tomography
55%
Prognostic Factor
12%
Progression Free Survival
58%
Reduced Intensity Conditioning
27%
Rituximab
35%
Salvage Therapy
26%
Stem Cell Therapy
27%
Keyphrases
95% Confidence Interval
35%
Acute Leukemia
18%
Acute Myeloid Leukemia
54%
Adult Patients
16%
Aggressive non-Hodgkin Lymphoma
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
49%
Autologous Stem Cell Transplantation (auto-SCT)
33%
B-cell Malignancies
14%
Bendamustine
23%
BNT162b2
18%
Bone Marrow
15%
CD19
19%
CD19 chimeric Antigen Receptor T Cells
34%
Cell Therapy
14%
Chemotherapy
16%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Chronic Lymphocytic Leukemia
20%
Complete Remission
22%
Complete Response
22%
COVID-19
25%
Cyclophosphamide
14%
Cytokine Release Syndrome
17%
Diffuse Large B-cell Lymphoma (DLBCL)
24%
Engraftment
18%
Hazard Ratio
28%
Hematological Malignancies
17%
Hematotoxicity
14%
High Risk
18%
High-dose Chemotherapy
18%
Hodgkin Lymphoma
16%
Ibrutinib
18%
Induction Chemotherapy
14%
Large B-cell Lymphoma
29%
Leukemia Patients
43%
Leukocytes
14%
Lymphoma
14%
Lymphoma Patients
20%
Multiple Myeloma
36%
Non-Hodgkin Lymphoma
26%
Non-relapse Mortality
18%
Overall Survival
54%
Phase I Study
15%
Positron Emission Tomography/computed Tomography (PET/CT)
33%
Progression-free Survival
36%
Relapsed/refractory
26%
Relapsed/refractory Acute Myeloid Leukemia
14%
Rituximab
34%
Salvage Therapy
23%
Stem Cell Transplantation
23%
Transplantation
17%
Immunology and Microbiology
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Allogeneic Stem Cell Transplantation
9%
Allograft
11%
Autologous Stem Cell Transplantation
7%
B Cell
92%
CD19
80%
CD20
7%
CD28
7%
CD3 Antigen
11%
CD34
14%
Central Nervous System
10%
Chimeric Antigen Receptor
37%
Chimeric Antigen Receptor T-Cell
84%
Chimeric Antigen Receptor T-Cell Therapy
49%
COVID-19
19%
CXCR4
14%
Cyclophosphamide
10%
Cytokine Release Syndrome
18%
Dexamethasone
10%
Drug Megadose
8%
Effector Cell
7%
Engraftment
11%
Graft-Versus-Host Disease
9%
Hematopoietic Cell
26%
Hematopoietic Stem Cell Transplantation
9%
Immunotherapy
8%
In Vitro
14%
Infection
15%
Infectious Disease
15%
Lactic Acid
7%
Leukemia Cell
13%
Leukocyte
7%
Long Term Survival
6%
Lymphocyte
9%
Multiple Myeloma
34%
Myeloid
48%
Neutralizing Antibody
9%
NOD SCID Mouse
11%
Overall Survival
47%
Phosphatase
10%
Polatuzumab Vedotin
9%
Positron Emission Tomography-Computed Tomography
11%
Pretreatment
9%
Progression Free Survival
27%
Rituximab
19%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Stem Cell
13%
Stromal Cell-Derived Factor 1
16%
T Cell
19%
Thalidomide
9%